Opioid antagonists: all 625 studies that test it

Page 5 of 7. Open to participants first (43), then studies with results posted, then the rest; newest registration first within each.

• The Impact of the Opiate Antagonist Naltrexone on the Emotional Valence of DreamsCompletedNCT02792140Phase 4
• Nalmefene in Alcohol Dependence and Borderline Personality DisorderStatus unknownNCT02752503Not applicable
• Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy VolunteersCompletedNCT02750748Phase 1
• Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy ParticipantsCompletedNCT02745912Phase 1
• Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy ParticipantsCompletedNCT02735603Phase 1
• Buccal Versus Injectable Naloxone: a Phase I Healthy Volunteer StudyStatus unknownNCT02733822Phase 1
• Evaluation of Naltrexone as a Treatment for Self-injurious BehaviorWithdrawnNCT02726035Phase 4
• The Effect of Naloxegol on Refractory Constipation in the Intensive Care UnitWithdrawnNCT02705378Phase 3
• Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia During a Burn InjuryCompletedNCT02684669Phase 2
• Validation of a Test System for Development of Medications for AlcoholismCompletedNCT02652585Phase 3
• A Study in a Human Laboratory Model of Smoking BehaviorCompletedNCT02641028Phase 2
• Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene VariationCompletedNCT02639273Phase 1
• Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric SurgeryWithdrawnNCT02616315Phase 4
• Bioavailability of Nasal Naloxone and Injected Naloxone ComparedCompletedNCT02598856Phase 1
• Medication-Assisted Treatment for Youth With Substance Use DisordersCompletedNCT02593474Phase 1
• Study of Methylnaltrexone in Opioid-Induced Constipation PatientsStatus unknownNCT02574819Phase 2/3
• Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy VolunteersCompletedNCT02572089Phase 1
• Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward ImpulsivityCompletedNCT02557984Not applicable
• The Effect of Regular Naltrexone Dosing on Disordered GamblersCompletedNCT02537197Phase 1
• Early Postoperative Administration of Oxycodone +/- Naloxone and Duration of Epidural AnalgesiaCompletedNCT02516059Phase 4
• A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male VolunteersCompletedNCT02504463Phase 1
• Assessment of the Effect of Naltrexone on Lofexidine Single Dose Pharmacokinetics in Healthy SubjectsCompletedNCT02446002Phase 1
• Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled AnalgesiaCompletedNCT02416115Not applicable
• Pharmacodynamics and Arteriovenous Differences of Naloxone in Healthy Participants Exposed to an OpioidCompletedNCT02405988Not applicable
• A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained SubjectsCompletedNCT02391571Phase 3
• Single-dose of Nalmefene to Modulate Neural Alcohol Cue ReactivityTerminatedNCT02372318Early Phase 1
• The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid AntagonismCompletedNCT02362256Not applicable
• Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients With EpilepsyCompletedNCT02332447Phase 3
• Biomarkers of Injectable Extended Release Naltrexone TreatmentCompletedNCT02324725Phase 4
• Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital UseCompletedNCT02307721Phase 1/2
• Treatment of Chronic Itch in Atopic Dermatitis (Eczema): Nerve FunctionCompletedNCT02268448Phase 1
• Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Morphine and Naloxone on Motivation (MBBAnalgesic)CompletedNCT02267304Phase 2
• FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 StudyWithdrawnNCT02218775Phase 1
• A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid UsersCompletedNCT02218021Phase 1
• Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed UseCompletedNCT02197598Phase 4
• Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary CareTerminatedNCT02195817Phase 4
• Feasibility Study of Oral Naloxone for Treatment of Methadone-induced ConstipationCompletedNCT02137213Phase 2
• Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC PatientsCompletedNCT02099591Phase 1
• Drug Interaction & Methadone & BuprenorphineCompletedNCT02045693Phase 1
• Treatment of Chronic Pain From OsteoarthritisWithdrawnNCT02032927Phase 4
• Effect of High Dose Naloxone on Secondary HyperalgesiaCompletedNCT01935206Phase 1
• Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy SubjectsCompletedNCT01934166Phase 1
• Nasal Naloxone for Narcotic OverdoseStatus unknownNCT01912573Phase 4
• Methylnaltrexone Pharmacokinetics in Neurointensive Care PatientsCompletedNCT01889290Phase 1
• Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release NaltrexoneCompletedNCT01882361Phase 2/3
• The Relationships Between the Noradrenergic, Opioid and Pain SystemWithdrawnNCT01851486Not applicable
• A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid UsersCompletedNCT01825447Phase 1
• Low Dose Naltrexone in Symptomatic Inflammatory Bowel DiseaseWithdrawnNCT01810185Phase 2
• Methylnaltrexone Use for Opioid-induced Postoperative ConstipationCompletedNCT01773096Phase 4
• To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social DrinkersCompletedNCT01738867Phase 1
• Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in NorwayCompletedNCT01717963Phase 3
• Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent SubjectsWithdrawnNCT01713803Phase 3
• Pharmacotherapy for Alcohol Dependence in Convicted Drinking DriversTerminatedNCT01638377Phase 4
• Open Label, Healthy Volunteers, Bioequivalence Study With NaloxegolCompletedNCT01623609Phase 1
• Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy SubjectsCompletedNCT01596777Phase 1
• Effects of Methylnaltrexone in Comparison to Naloxone on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time.CompletedNCT01596764Phase 1
• Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of NaloxegolCompletedNCT01594619Phase 1
• The Effects of ∆-9-THC and Naloxone in HumansCompletedNCT01591629Early Phase 1
• Transfer of Subjects From Subutex/Suboxone to RBP-6300CompletedNCT01582347Phase 2
• Clinical Trial on Binge Eating Disorder, Treatment With Naloxone SprayStatus unknownNCT01567670Phase 2/3
• Pre-Release VIVITROL for Opioid Dependent InmatesCompletedNCT01563718Phase 4
• The Effects of Treatment With Naltrexone in Alcohol and Cannabis-dependent PatientsStatus unknownNCT01560013Not applicable
• Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118CompletedNCT01533870Phase 1
• Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118CompletedNCT01520896Phase 1
• Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECTCompletedNCT01471145Phase 4
• Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)CompletedNCT01449565Phase 2
• Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back PainCompletedNCT01415895Phase 2
• Open-label Study to Assess the Pharmacokinetics of NKTR-118 in Patients With Impaired Hepatic FunctionCompletedNCT01392807Phase 1
• Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in RussiaCompletedNCT01389167Phase 3
• Improved Strategies for Outpatient Opioid DetoxificationCompletedNCT01377610Phase 1
• Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use DisorderCompletedNCT01377168Phase 4
• Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal FunctionCompletedNCT01372826Phase 1
• Safety and Gastrointestinal Effects of Intravenous MethylnaltrexoneCompletedNCT01367587Phase 2
• Naloxone and Intravenous Methylnaltrexone Effects on Bladder FunctionCompletedNCT01367561Phase 1
• Intravenous (IV) Methylnaltrexone (MNTX) in the Prevention of Post-Operative IleusCompletedNCT01367548Phase 2
• Effects of MNTX on CYP450 2D6 in Metabolizers of DextromethorphanCompletedNCT01367535Phase 1
• Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal FunctionCompletedNCT01367509Phase 1
• Pharmacokinetics and Bioavailability of Single Subcutaneous Doses of Methylnaltrexone Versus Intravenous DoseCompletedNCT01367496Phase 1
• Study of the Pharmacokinetics of Intravenous Administered 14C-MNTXCompletedNCT01367483Phase 1
• Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTXCompletedNCT01366378Phase 1
• Study of Pharmacokinetics, Safety and Tolerability of Intravenous Methylnaltrexone BromideCompletedNCT01366365Phase 1
• Tolerance and Pharmacokinetics Study of MNTX TabletsCompletedNCT01366339Phase 1
• Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult SubjectsCompletedNCT01366326Phase 1
• ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With CocaineCompletedNCT01366001Phase 1
• Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy SubjectsCompletedNCT01365000Phase 1
• Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac RepolarizationCompletedNCT01363323Phase 1
• Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With OpiatesWithdrawnNCT01360372Phase 3
• Absorption, Distribution, Metabolism and Excretion (ADME) Study With Single Oral Administration of [14C] NKTR-118CompletedNCT01348724Phase 1
• Role of the Endogenous Opioid System Underlying Modulation of Experimental PainWithdrawnNCT01327326Not applicable
• A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male SubjectsCompletedNCT01325415Phase 1
• Single and Multiple Ascending Dose Study for NKTR-118 and Cross-over Study to Investigate the Effect of Food for NKTR-118 in Japanese Healthy SubjectsCompletedNCT01318655Phase 1
• Randomized Trial of Intranasal Versus Intravenous Naloxone in Level of Consciousness in Suspected Opioid OverdoseCompletedNCT01293058Phase 2
• Drug-Drug Interaction Study Between Telaprevir and BuprenorphineCompletedNCT01275599Phase 1
• A Study of Brain Receptor Occupancy in Healthy SubjectsCompletedNCT01232439Phase 1
• Stress, Hormones, and EatingCompletedNCT01175512Early Phase 1
• Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+CompletedNCT01174914Phase 2
• Oxycodone/Naloxone (OXN) Combination in Moderate to Severe Non-malignant PainCompletedNCT01167699Phase 3
• Naloxone Methadone Combination (NAMEKO)WithdrawnNCT01160432Not applicable
• Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality DisorderCompletedNCT01133301Phase 2
• Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill PatientsTerminatedNCT01117376Phase 2

← Opioid antagonists overview